Publicaciones en las que colabora con MARIA LUISA FERRANDIZ MANGLANO (27)

2024

  1. Adenosine A2B receptor agonist improves epidermal barrier integrity in a murine model of epidermal hyperplasia

    Biomedicine and Pharmacotherapy, Vol. 173

  2. Osteostatin Mitigates Gouty Arthritis through the Inhibition of Caspase-1 Activation and Upregulation of Nrf2 Expression

    International Journal of Molecular Sciences, Vol. 25, Núm. 5

2022

  1. Osteostatin Inhibits M-CSF+RANKL-Induced Human Osteoclast Differentiation by Modulating NFATc1

    International journal of molecular sciences, Vol. 23, Núm. 15

2019

  1. Osteostatin inhibits collagen-induced arthritis by regulation of immune activation, pro-inflammatory cytokines, and osteoclastogenesis

    International Journal of Molecular Sciences, Vol. 20, Núm. 16

2016

  1. Chondroprotective effects of the combination chondroitin sulfate-glucosamine in a model of osteoarthritis induced by anterior cruciate ligament transection in ovariectomised rats

    Biomedicine and Pharmacotherapy, Vol. 79, pp. 120-128

2015

  1. Effects of BIS076 in a model of osteoarthritis induced by anterior cruciate ligament transection in ovariectomised rats

    BMC Musculoskeletal Disorders, Vol. 16, Núm. 1

2014

  1. Influence of age on osteoarthritis progression after anterior cruciate ligament transection in rats

    Experimental Gerontology, Vol. 55, pp. 44-48

2012

  1. Analysis of early biochemical markers and regulation by tin protoporphyrin IX in a model of spontaneous osteoarthritis

    Experimental Gerontology, Vol. 47, Núm. 5, pp. 406-409

2010

  1. Elaboración de videos didácticos como alternativa a los ensayos in vivo en las prácticas de farmacología

    Ars pharmaceutica, Vol. 51, Núm. 1, pp. 162-168

  2. Farmacinema: recurso docente en el aprendizaje de Farmacología y Farmacia Clínica

    Ars pharmaceutica, Vol. 51, Núm. 1, pp. 169-176

2007

  1. Evaluation of the anti-inflammatory and analgesic activity of Me-UCH9, a dual cyclooxygenase-2/5-lipoxygenase inhibitor

    Life Sciences, Vol. 80, Núm. 23, pp. 2108-2117

2006

  1. Phenylsulphonyl urenyl chalcone derivatives as dual inhibitors of cyclo-oxygenase-2 and 5-lipoxygenase

    Life Sciences, Vol. 78, Núm. 25, pp. 2911-2918

2005

  1. Influence of heme oxygenase 1 modulation on the progression of murine collagen-induced arthritis

    Arthritis and Rheumatism, Vol. 52, Núm. 10, pp. 3230-3238

2004

  1. Role of nuclear factor-κB and heme oxygenase-1 in the mechanism of action of an anti-inflammatory chalcone derivative in RAW 264.7 cells

    British Journal of Pharmacology, Vol. 142, Núm. 7, pp. 1191-1199

2001

  1. Inhibition of 5-lipoxygenase activity by the natural anti-inflammatory compound aethiopinone

    Inflammation Research, Vol. 50, Núm. 2, pp. 96-101

2000

  1. Co-regulation between cyclo-oxygenase-2 and inducible nitric oxide synthase expression in the time-course of murine inflammation

    Naunyn-Schmiedeberg's Archives of Pharmacology, Vol. 361, Núm. 1, pp. 98-106

1999

  1. Inhibition of human sPLA2 and 5-lipoxygenase activities by two neo- clerodane diterpenoids

    Life Sciences, Vol. 64, Núm. 19

1998

  1. A new cacospongionolide inhibitor of human secretory phospholipase A2 from the tyrrhenian sponge Fasciospongia cavernosa and absolute configuration of cacospongionolides

    Journal of Natural Products, Vol. 61, Núm. 7, pp. 931-935

  2. Anti-inflammatory activity in mice of extracts from Mediterranean marine invertebrates

    Life Sciences, Vol. 62, Núm. 9

  3. Suppression of leukotriene B4 and tumour necrosis factor α release in acute inflammatory responses by novel prenylated hydroquinone derivatives

    Naunyn-Schmiedeberg's Archives of Pharmacology, Vol. 357, Núm. 5, pp. 565-572